Broos Caroline E, Hendriks Rudi W, Kool Mirjam
Department of Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands.
Curr Opin Pulm Med. 2016 Sep;22(5):476-83. doi: 10.1097/MCP.0000000000000303.
Although the aetiology of sarcoidosis is not yet completely understood, immunological changes within the T-cell compartment are characteristic for an exaggerated antigen-driven immune response. In this review, we describe the most recent findings on T-cell subset responses and regulation in sarcoidosis. We discuss how future immunological research can advance the field to unravel pathobiological mechanisms of this intriguingly complex disease.
Research into the field of T-cell plasticity has recently challenged the long-held T helper type 1 (Th1) paradigm in sarcoidosis and striking parallels with autoimmune disorders and common variable immunodeficiency were recognized. For instance, it was demonstrated that Th17.1-cells rather than Th1-cells are responsible for the exaggerated IFN-γ production in pulmonary sarcoidosis. Furthermore, impaired regulatory T-cell function and alterations within the expression of co-inhibitory receptors that control T-cell responses, such as PD-1, CTLA-4 and BTNL2, raise new questions regarding T-cell regulation in pulmonary sarcoidosis.
It becomes increasingly clear that Th17(.1)-cells and regulatory T-cells are key players in sarcoidosis T-cell immunology. New findings on plasticity and co-inhibitory receptor expression by these subsets help build a more comprehensive model for T-cell regulation in sarcoidosis and will finally shed light on the potential of new treatment modalities.
尽管结节病的病因尚未完全明确,但T细胞区室的免疫变化是过度抗原驱动免疫反应的特征。在本综述中,我们描述了结节病中T细胞亚群反应和调节的最新发现。我们讨论了未来的免疫学研究如何推动该领域发展,以揭示这种极其复杂疾病的病理生物学机制。
T细胞可塑性领域的研究最近对结节病中长期存在的1型辅助性T细胞(Th1)范式提出了挑战,并认识到与自身免疫性疾病和常见可变免疫缺陷有显著相似之处。例如,已证明在肺部结节病中,产生过量干扰素-γ的是Th17.1细胞而非Th1细胞。此外,调节性T细胞功能受损以及控制T细胞反应的共抑制受体(如程序性死亡受体1、细胞毒性T淋巴细胞相关蛋白4和B7家族成员2)表达的改变,引发了关于肺部结节病中T细胞调节的新问题。
越来越清楚的是,Th17(.1)细胞和调节性T细胞是结节病T细胞免疫学的关键参与者。这些亚群在可塑性和共抑制受体表达方面的新发现有助于建立一个更全面的结节病T细胞调节模型,并最终阐明新治疗方式的潜力。